CCDC66: A Promising Drug Target and Biomarker for Neurodegenerative Disorders

Target Name: CCDC66

NCBI ID: G285331

CCDC66

CCDC66: A Promising Drug Target and Biomarker for Neurodegenerative Disorders

Introduction

CDC66, or Coiled-coil domain-containing protein 66 (isoform 1), is a protein that has been identified as a potential drug target and biomarker for various neurodegenerative disorders. Its unique structure, which consists of a long coiled-coil and a transmembrane domain, has led to a significant impact in the study of protein-protein interactions and the development of new therapeutic approaches.

CDC66 is a member of the CCDC family, which includes several structurally similar proteins that share a conserved coiled-coil domain. These proteins are involved in various cellular processes, including cell signaling, neurotransmission, and stress response. The CCDC family has been implicated in the development and progression of neurodegenerative disorders, making it an attractive target for drug development.

CDC66 Functions and Interactions

CDC66 functions as a protein that can interact with other proteins both within and outside the cell membrane. Its coiled-coil domain plays a crucial role in this interaction, as it allows the protein to change its shape and create multiple interfaces with other molecules. These interfaces provide a platform for various interactions, such as protein-protein interactions, protein-lipid interactions, and DNA-protein interactions.

One of the most significant interactions of CDC66 is its interaction with the protein tau, which is a key protein in the development of neurodegenerative disorders, including Alzheimer's disease. tau is known to form aggregates, which are thought to contribute to the progressive neurotoxicity seen in these disorders. By targeting CDC66, researchers have the potential to reduce tau aggregation and improve neurodegeneration.

Another interaction of CDC66 is its interaction with the protein GABA, which is involved in the regulation of neural activity. This interaction may contribute to the neuroprotective effects of GABA, as CDC66 has been shown to protect GABA-interactive neurons from neurotoxicity.

CDC66 as a Biomarker

The ability of CDC66 to interact with multiple proteins makes it an attractive biomarker for various neurodegenerative disorders. One of the key advantages of using CDC66 as a biomarker is its high sensitivity to changes in the expression level, making it an reliable indicator of disease status.

CDC66 has been shown to be expressed in the brains of individuals with various neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally, studies have shown that changes in the expression level of CDC66 are associated with the progression of neurodegenerative disorders.

In addition to its use as a biomarker, CDC66 has also been identified as a potential drug target. Its unique structure and the interaction it has with other proteins make it an attractive target for small molecules and other therapeutic compounds.

Conclusion

In conclusion, CDC66 is a protein that has the potential to be a drug target and biomarker for various neurodegenerative disorders. Its unique structure and the interactions it has with other proteins make it an attractive target for small molecules and other therapeutic compounds. Further research is needed to fully understand the role of CDC66 in neurodegenerative disorders and to develop effective treatments.

Protein Name: Coiled-coil Domain Containing 66

Functions: Microtubule-binding protein required for ciliogenesis (PubMed:28235840). May function in ciliogenesis by mediating the transport of proteins like BBS4 to the cilium, but also through the organization of the centriolar satellites (PubMed:28235840). Plays a role in retina morphogenesis and/or homeostasis (By similarity)

The "CCDC66 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC66 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets